- Home
- RDCM vs VRXA Comparison
RDCM vs VRXA Comparison
Compare RDCM & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | VRXA |
|---|---|---|
| Founded | 1985 | 2021 |
| Country | Israel | Germany |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.1M | 161.2M |
| IPO Year | 1999 | 2025 |
Fundamental Metrics
Financial Performance| Metric | RDCM | VRXA |
|---|---|---|
| Price | $10.81 | $1.21 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 56.5K | ★ 148.9K |
| Earning Date | 11-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $0.90 |
| 52 Week High | $16.74 | $4.50 |
Technical Indicators
Market Signals| Indicator | RDCM | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 56.59 | 57.36 |
| Support Level | $10.72 | $1.00 |
| Resistance Level | $11.26 | $1.25 |
| Average True Range (ATR) | 0.48 | 0.12 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 57.23 | 76.78 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.